An observational study in HFrEF - Heart Failure With Reduced Ejection Fraction and Guideline Adherence, sponsored by Jasper Brugts MD PhD. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Jasper Brugts MD PhD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.
Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 13th largest by planned enrollment of the 76 observational ones that give a count, is one of 18 that started in 2026, is one of 76 observational ones, reaches primary completion later than 64 of the 79 other live ones, and was the 310th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Netherlands, United States, Argentina and 29 more countries
Ages 18+
Eli Lilly and Company · Sites in Netherlands, United States, Japan and 2 more countries
Ages 18–65
BrioHealth BV · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Novo Nordisk A/S · Sites in Netherlands, United States, Argentina and 24 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
313 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 55 · Phase 3 68 · Phase 4 12
First in 1983; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 284 across the 234 interventional studies, 236 across the 76 observational. Of the 200 that completed or were terminated, 84 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
179 of 313 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jasper Brugts MD PhD as lead sponsor.
Jasper Brugts MD PhD has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
15 of the studies in Heart Failure with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06137261Franciscus GasthuisScreening Adults With Obesity to Reduce Heart Failure Events | 2026-12-08 |
| NCT06735404Radboud University Medical CenterRAPIDE: The Feasibility of a Hybrid Care Model | 2027-03 |
| NCT06641362VDI TechnologiesUltra-High Frequency - Electrocardiogram (UHF-ECG) for the Diagnosis of Ventricular Electrical Dyssynchrony (VED) | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 313 studies in Heart Failure with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4 pillars of guideline directed medical therapy (GDMT) in HFrEF patients will help to further improve the implementation of GDMT.
Data will be used from the national HF registry in the Netherlands. Two groups will be studied, one where the HCP receives the mirror information on GDMT and one where both the patient and the HCP receive the mirror information on GDMT. GDMT or the 4 pillars treatment is standard of care as recommended by the ESC HF guidelines, indicated for all HFrEF patients. The project is a quality of care registry and health care evaluation to optimize adherence to the HF guidelines.
The IMPLEMENT HF is a sequel study to the TITRATE HF study that has shown that the level of GDMT prescription in de novo HFrEF can be further improved. The investigators hypothesize that mirror information about actual levels of GDMT helps the physician and patient optimize GDMT as recommended in the guideline. The IMPLEMENT is a registry based study in 1500 with de novo HFrEF patients, in which mirror information on GDMT (4 pillars) prescription levels will be shown to the treating physician. In a second group (50%) both the physician and patient will receive the mirror information on the prescription of GDMT. For diversity, the investigators aim to include 50% elderly and 50% women in to the registry. The primary endpoint is the prescription level of GDMT. Secondary endpoints are the dosing levels of GDMT (% target dose) and incident clinical events.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Patients with de novo / newly diagnosed heart failure with reduced ejection fraction
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
At enrollment the patient has an established diagnosis of heart failure with reduction .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Guideline recommended drug therapy for HFrEF with mirror information to HCP
Guideline recommended drug therapy for HFrEF with mirror information to HCP and patient.
The prescription level (%) of GDMT / 4 pillars in de novo HFrEF patients.
The prescription level (%) of GDMT / 4 pillars in patients with de novo HFrEF at specific time moments durign 1 year (6 weeks, 3 Months , 6 Months, 12 Months)
Time frame: 1 year of follow-up
The % of target dose of GDMT prescribed in de novo HFrEF patients
The dosing level of a GDMT drug class as % of the guideline recommended dose during 1 year of follow-up.
Time frame: 1 year (evaluated at time moments 6 weeks, 3 Months, 6 Months, 12 Months).
Incident events
The incidence of all-cause mortality and HF hospitalisations during 12 months of follow-up (and the individual components of the composite outcome).
Time frame: 1 year of follow-up (12 months)
GDMT adherence in subgroups of age (elderly) and sex (men/women)
GDMT adherence in subgroups of age (elderly) and sex (men/women)
Time frame: 12 months
Plan to share: Undecided — The project is part of the NHR HF registry and follow the protocols and rules of the NHR on IPD accordingly (including GDPR/AVG), when applicable.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jun 2029, 34 months after the start.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 34 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.